All In Biotech

Drug Trial Radar · NCT07840820

Phase II/III Study of FXS5626 in Participants With Non-segmental Vitiligo

This is a Multicenter, Randomized, Double-blind, Placebo-controlled, Adaptive Seamless Design, Phase II/III Study Evaluating the Efficacy and Safety of FXS5626 in Participants With Non-segmental Vitiligo

Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 480 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

480

Planned (sponsor's estimate)

Start

Oct 30, 2026

Primary completion

Nov 10, 2027

Study completion Dec 8, 2027

Sponsor

Sponsor type
Industry
First posted
Sep 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled, adaptive seamless design, Phase II/III study evaluating the efficacy and safety of FXS5626 in participants with non-segmental vitiligo.

Conditions

  • Non-segmental Vitiligo

Interventions

  • Intervention1: FXS5626 TabletsDrug

    FXS5626 tablets administered orally twice daily (BID) for 24 weeks.

  • Intervention2: FXS5626 TabletsDrug

    FXS5626 tablets administered orally twice daily (BID) for 24 weeks.

  • Intervention3: FXS5626 TabletsDrug

    FXS5626 tablets administered orally twice daily (BID) for 24 weeks.

  • Intervention4: FXS5626 TabletsDrug

    FXS5626 tablets administered orally twice daily (BID) for 52 weeks.

  • Intervention5: FXS5626 Placebo TabletsDrug

    FXS5626 placebo tablets administered orally twice daily (BID) for 24 weeks.

  • Intervention6: FXS5626 Placebo TabletsDrug

    FXS5626 placebo tablets administered orally twice daily (BID) for 52 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change from baseline in facial vitiligo area scoring index (F-VASI) at week 24 in Phase 2 study.Time frame: 24 weeks
  2. Proportion of participants achieving Facial Vitiligo Area Scoring Index 75 (F-VASI 75, at least 75% improvement from baseline) at Week 52 in Phase 3 study.Time frame: 52 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Huashan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.